NEW YORK, NY / ACCESSWIRE / November 22, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Class Period: May 11, 2021 - October 5, 2021
Lead Plaintiff Deadline: January 18, 2022
According to the complaint, Ginkgo Bioworks Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's failure to derive real revenue from third-party customers left it almost completely dependent on related parties; (2) as a result, most, if not all, of the Company's revenue came from related parties the Company created, funded, or controlled through its ownership and board seats; (3) the Company was misclassifying and underreporting related party revenue in order to conceal the Company's near total-dependence on related parties; (4) many of the Company's new R&D partners are undisclosed related parties and/or façades; (5) as a result, the Company's valuation was significant less than Defendants disclosed to investors; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Learn about your recoverable losses in DNA: https://www.kleinstocklaw.com/pslra-1/ginkgo-bioworks-holdings-inc-loss-submission-form?id=21476&from=1
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Class Period: January 13, 2020 - September 3, 2021
Lead Plaintiff Deadline: December 22, 2021
The complaint alleges that during the class period BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in BMRN: https://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?id=21476&from=1
Snap Inc. (NYSE:SNAP)
Class Period: July 22, 2020 - October 21, 2021
Lead Plaintiff Deadline: January 10, 2022
Throughout the class period, Snap Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Apple's privacy changes would have, and were having, a material impact on the Company's advertising business; (2) Snap overstated its ability to transition its advertising with Apple's privacy changes; (3) Snap knew of, but downplayed, the risks of the impact that Apple's privacy changes had on the Company's advertising business; (4) Snap overstated its commitment to privacy; and (5) as a result of the foregoing, Defendants' public statements and statements to journalists were materially false and/or misleading at all relevant times.
Learn about your recoverable losses in SNAP: https://www.kleinstocklaw.com/pslra-1/snap-inc-loss-submission-form-2?id=21476&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/674194/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-DNA-BMRN-and-SNAP